New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites by Jose A. Garcia-Salcedo et al.
fphar-07-00351 September 26, 2016 Time: 16:52 # 1
REVIEW
published: 28 September 2016
doi: 10.3389/fphar.2016.00351
Edited by:
Harry P. De Koning,
University of Glasgow, UK
Reviewed by:
Andrei Adrian Tica,
University of Medicine and Pharmacy
of Craiova, Romania
Constantin Ion Mircioiu,
Carol Davila University of Medicine
and Pharmacy, Romania
*Correspondence:
José A. Garcia-Salcedo
jags@genyo.es
Specialty section:
This article was submitted to
Drug Metabolism and Transport,
a section of the journal
Frontiers in Pharmacology
Received: 24 July 2016
Accepted: 16 September 2016
Published: 28 September 2016
Citation:
Garcia-Salcedo JA,
Unciti-Broceta JD, Valverde-Pozo J
and Soriano M (2016) New
Approaches to Overcome Transport
Related Drug Resistance
in Trypanosomatid Parasites.
Front. Pharmacol. 7:351.
doi: 10.3389/fphar.2016.00351
New Approaches to Overcome
Transport Related Drug Resistance
in Trypanosomatid Parasites
Jose A. Garcia-Salcedo1,2*, Juan D. Unciti-Broceta1, Javier Valverde-Pozo1,2 and
Miguel Soriano2,3
1 Unidad de Enfermedades Infecciosas y Microbiología, Instituto de Investigación Biosanitaria, ibs.GRANADA, Hospitales
Universitarios de Granada – Universidad de Granada, Granada, Spain, 2 Centro de Genómica e Investigación Oncológica –
Pfizer/Universidad de Granada/Junta de Andalucía, Granada, Spain, 3 Departamento de Agronomía, Universidad de Almería,
Almería, Spain
Leishmania and Trypanosoma are members of the Trypanosomatidae family that cause
severe human infections such as leishmaniasis, Chagas disease, and sleeping sickness
affecting millions of people worldwide. Despite efforts to eradicate them, migrations are
expanding these infections to developing countries. There are no vaccines available and
current treatments depend only on chemotherapy. Drug resistance is a major obstacle
for the treatment of these diseases given that existing drugs are old and limited, with
some having severe side effects. Most resistance mechanisms developed by these
parasites are related with a decreased uptake or increased efflux of the drug due to
mutations or altered expression of membrane transporters. Different new approaches
have been elaborated that can overcome these mechanisms of resistance including
the use of inhibitors of efflux pumps and drug carriers for both active and passive
targeting. Here we review new formulations that have been successfully applied to
circumvent resistance related to drug transporters, opening alternative ways to solve
drug resistance in protozoan parasitic diseases.
Keywords: trypanosomatid parasites, drug transport, surface transporter, efflux pumps, drug resistance,
nanocarriers
INTRODUCTION
Parasitic protozoa are responsible for some of the most prevalent diseases in humans, threatening
the lives of nearly 1.250 million people around the world (Lozano et al., 2012). Among them,
trypanosomatids are responsible for diseases such as human African trypanosomiasis, Chagas
disease and leishmaniasis (Table 1). Together, these neglected diseases cause more than 52.000
fatalities annually and the loss of 5 million disability-adjusted life years in developing countries
worldwide (Lozano et al., 2012; Hotez et al., 2014).
Despite their high prevalence, there is no effective vaccine against any of these pathogens and
their treatment is based only on chemotherapy. However, the actual number of effective drugs is
very low, most of them having high toxicity, a situation that has worsened by the development of
resistance to almost all of them. Even the newest drugs are being compromised by the emergence
of resistance in parasitic trypanosomatids (Cojean et al., 2012; Zingales et al., 2015).
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The recent call for elimination and eradication of neglected
tropical diseases requires research from multiple fronts, including
developing strategies for the efficient delivery of current
medicines and to overcome drug resistance.
THE DISEASES AND THEIR
PATHOGENESIS
Human African Trypanosomiasis
African trypanosomiasis is a vector-borne disease that threatens
millions of people living in impoverished rural parts of sub-
Saharan Africa, where they are at risk of infection. It is caused by
the flagellated protozoa Trypanosoma brucei and transmitted by
tsetse flies of the genus Glossina. The subspecies T. b. gambiense
and T. b. rhodesiense cause human African trypanosomiasis,
also called sleeping sickness (Table 1). In addition, the parasite
infects domestic animals, causing nagana, a devastating disease
of livestock in Africa. Probably, no other disease except malaria,
HIV and tuberculosis, has hindered the development of a
continent as has trypanosomiasis in Africa. The disease presents
two stages, the early stage or hemolymphatic phase and the late
stage or neurological phase which is characterized by invasion
of the central nervous system. The East African variant is a
chronic disease which takes years to progress, while West African
trypanosomiasis is an acute infection in which the late stage
develops in a few weeks or months after infection (Welburn et al.,
2016). Human African trypanosomiasis is fatal if there is no a
chemotherapy intervention (Matthews, 2015).
Leishmaniasis
Leishmaniasis is a vector-borne disease caused by different
species of the genus Leishmania, (trypanosomatidae family) and
transmitted by phlebotomine sandflies. Clinical manifestations
vary from local skin lesions and destructive mucosal
inflammation to disseminated visceral infection (kala-azar),
depending on infecting species and host factors (Murray et al.,
2005; Tripathi et al., 2007). Epidemiology and immunopathology
are also diverse with multiple endemic regions in areas of the
tropics, subtropics, and southern Europe. A total of 350 million
people are considered at risk with an estimated 1.5–2 million
new cases per year, up to 500.000 of which are visceral and
about 1.5 million are mucocutaneous. Visceral leishmaniasis
is fatal if untreated, causing 20.000 to 30.000 deaths annually
(Table 1), whereas cutaneous leishmaniasis has a tendency to
spontaneously self-cure (den Boer et al., 2011). All forms of the
disease share three pathogenetic features: tissue macrophages are
targeted cells and support intracellular parasite replication; the
host immunoinflammatory response regulates the outcome of
disease; and there is a persistent tissue infection (Murray et al.,
2005). Due to its higher impact on global health we will focus in
this review on visceral leishmaniasis and the Leishmania species
responsible for the disease (L. donovani and L. infantum).
Chagas Disease
One of the most serious health problems in the American
continent is Chagas disease, caused by the intracellular parasite
T. cruzi (Table 1). Infection is transmitted by reduviid insect
vectors, but can also result from vertical transmission from
mother to fetus (Carlier et al., 2015), by oral ingestion
of contaminated food or drink (Noya et al., 2015), blood
transfusions (Young et al., 2007) and organ transplants (Kun
et al., 2009).
Chagas disease is endemic to Latin America where more than
6 million people are infected, and as a result of migration is an
emerging disease in traditionally non-endemic countries (Coura
and Vinas, 2010; Gascon et al., 2010). While infection can remain
asymptomatic for many years, an estimated 30% of individuals
infected with T. cruzi develop potentially fatal cardiomyopathy,
and gastrointestinal tract lesions (Nunes et al., 2013).
CURRENT TREATMENTS
Human African trypanosomiasis therapy relies only on four
drugs: pentamidine, suramin, melarsoprol and eflornithine, also
known as DFMO and treatment is dependent on the subspecies
and disease stage (Table 1) (Delespaux and de Koning, 2007;
Babokhov et al., 2013). Pentamidine and suramin are used to treat
early stage trypanosomiasis, when the parasite is restricted to the
blood/lymphatic system. Pentamidine is the first-line treatment
TABLE 1 | Trypanosomatid diseases.
Disease human African trypanosomiasis Visceral leishmaniasis Chagas disease
Causative agents Trypanosoma brucei gambiense
Trypanosoma brucei rhodesiense
Leishmania donovani
Leishmania infantum
Trypanosoma cruzi
Areas of endemicity West and central Africa (T. b. gambiense) East
and southern Africa (T. b. rhodesiense)
India, Bangladesh, Nepal, Sudan, Ethiopia,
and Brazil
Central and South America
Deaths per annum ∼10 000 ∼30 000 ∼12 000
Current front-line therapies Early stage: pentamidine and suramin
Late stage: melarsoprol, eflornithine
monotherapy a and NECT
(nifurtimox-eflornithine combination therapy)
Amphotericin B and lipid formulations
Miltefosine
Pentavalent antimonials
Paromomycin
Acute: nifurtimox and benznidazole
Indeterminate and chronic stages: no
standard treatments
Transporters associated to
resistance
Aquaglyceroporin 2 (pentamidine and
melarsoprol)
TbAAT6 (eflornithine)
ABC transporters (nifurtimox)
ABC transporters: PRP1 (pentamidine and
antimonials)
Aquaglyceroporin 1 (antimonials)
LdMT (miltefosine)
ABC efflux pumps
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for T. b. gambiense infections and suramin covers the treatment
of T. b. rhodesiense trypanosomiasis. Neither of these compounds
crosses the blood-brain barrier, being useless to treat central
nervous system infections.
Melarsoprol and eflornithine are used in the late stage of
the disease, once the parasite has invaded the central nervous
system. Melarsoprol was introduced in the mid-20th century and
is currently the only effective drug against the late stage of human
African trypanosomiasis caused by both subspecies. Eflornithine
was the last drug to be introduced to treat human African
trypanosomiasis 50 years ago. The drug crosses the blood-brain
barrier but lacks effectiveness against T. b. rhodesiense.
The recently launched eflornithine-nifurtimox combined
therapy is the safest treatment for late-stage trypanosomiasis
(Priotto et al., 2009; Babokhov et al., 2013). The combination
of eflornithine and nifurtimox allows significant reduction
of eflornithine dose and treatment duration. However, like
eflornithine alone, this combined therapy is only effective
in the second stage of T. b. gambiense infections. This
leaves melarsoprol, an arsenical derivate that causes reactive
encephalopathy in about 10% of treated patients, as the only
effective drug against both T. b. rhodesiense and T. b. gambiense
late-stage infections. Because of this, the increasing rate of
melarsoprol treatment failures is alarming.
In the case of visceral leishmaniasis, the commercially
available first-line drugs for the treatment of the disease
are: pentavalent antimonials, amphotericin B, miltefosine,
pentamidine and paromomycin (Table 1) (Monge-Maillo and
Lopez-Velez, 2013; Elmahallawy and Agil, 2015). Like human
African trypanosomiasis, visceral leishmaniasis treatment
regimens are based on Leishmania species and geographic
region.
There are only two drugs now available for Chagas disease,
nifurtimox and benznidazole (Table 1). Both are very effective
if given soon after infection. However, treatment failures are not
infrequent (Munoz et al., 2013; Pinto et al., 2013) and both drugs
cause adverse effects (Jackson et al., 2010). Benznidazole is the
first choice for Chagas disease treatment due to lower side effects
than nifurtimox.
MODE OF ACTION, SURFACE
TRANSPORTERS AND RESISTANCES
To exert its action, a drug must be able to interact inside the
cell with its target/s at a concentration sufficient to inhibit its
biological activity. The emergence of resistance is associated
with this process. Parasites have evolved numerous ways to
overcome the toxicity of drugs. Most of them are based on
reducing the drug concentration that can access the target
or, alternatively, modifying the target molecule. Thus, drug
resistance might involve mutations causing the loss of their
uptake system (Figure 1). Once inside, drugs may be modified
and inactivated, excreted or relocated into vacuoles. Prodrugs
require activation to become effective and suppression or loss
of the activating process may lead to resistance. Another
mechanism of drug resistance is the alteration of drug/target
interaction by increasing the number target molecules or
their modification. Trypanosomatids employ these strategies to
develop resistance.
Suramin, a polysulphonated naphthylamine-based com-
pound, is a highly negatively charged molecule that accumulates
inside the trypanosome probably bound to human serum
proteins such as lipoproteins, albumin, globulins and fibrinogen
(Vansterkenburg et al., 1993). The mode of action of this drug
is not well established and is attributed to inhibition caused by
electrostatic interactions with essential proteins, enzymes etc. The
manner in which the drug enters the cell was postulated two
decades ago to be receptor-mediated endocytosis, but it was only
recently that evidence in this regard has been provided. Following
an RNAi approach, several genes whose down-regulation confers
resistance to suramin have been identified (Alsford et al., 2012).
Surprisingly, most of these genes code for proteins that are part
of the endocytic machinery and the endosomal compartment.
This finding has led ISG75 being proposed as the major surface
receptor for suramin uptake (Figure 2). Although suramin was
the first drug used to treat trypanosomiasis early last century,
resistance cases in the field have not yet been reported.
Pentamidine is a diamine that rapidly accumulates inside
trypanosomes against a concentration gradient up to millimolar
concentrations (Damper and Patton, 1976a,b; Berger et al.,
1995). It is known that pentamidine binds DNA, accumulates
in the mitochondria and collapses the mitochondrial membrane
potential but its precise mode of action has not been yet
satisfactory resolved.
Melarsoprol, an arsenical derivate, is unstable once in
circulation in the human body and is rapidly processed to the
more stable form melarsen oxide (Keiser et al., 2000). Once
inside the parasite, melarsen oxide reacts with trypanothione, a
metabolite exclusive to trypanosomes which is responsible for
detoxification of peroxides and for the redox balance of the cell
forming a toxic adduct known as MeltT.
It is well established that pentamidine and melarsoprol enter
the cell using the same transporter. The adenosine/adenine
transporter P2 was the first described transporter associated
with melarsoprol (Figure 2) (Carter and Fairlamb, 1993; Maser
et al., 1999) and pentamidine uptake (Carter et al., 1995; De
Koning, 2001). However, deletion of the gene generated a cell
with marginal resistance to both drugs (Matovu et al., 2003).
Recently aquaglyceroporin 2, a member of a family of surface
channel proteins involved in the transport of water and small
non-charged solutes, has been identified as the transporter
responsible for resistance to high concentrations of pentamidine
and melarsoprol (Alsford et al., 2012; Baker et al., 2012).
Although resistance to pentamidine has not been officially
reported, melarsoprol resistance is a common issue. A recent
study on T. b. gambiense demonstrated that rearrangements of
the aquaglyceroporin 2/3 locus accompanied by aquaglyceroporin
2 gene loss also occurs in the field, and that T. b. gambiense
carrying such mutations correlates with a resistance to
pentamidine and melarsoprol (Graf et al., 2013). Pentamidine
failures have commonly been dismissed as misdiagnosis of
late-stage sleeping sickness. Thus, we speculate that resistance to
pentamidine is likely present in the field.
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FIGURE 1 | Common mechanisms for drug resistance.
Pentamidine has also been used as an alternative therapy
for antimonial-refractory patients in visceral leishmaniasis. The
antileishmanial mechanisms of pentamidine include inhibition
of polyamine biosynthesis by inhibiting arginine and polyamine
uptake (Basselin et al., 2000), DNA minor groove binding
(Basselin et al., 1998), and inhibition of respiratory chain complex
II (Mehta and Shaha, 2004). Thus, the main target for the drug
seems to be the parasitic mitochondria.
Resistance to pentamidine in Leishmania has been reported
but the mechanisms are not clearly defined. Pentamidine
resistance protein 1 (PRP1), a member of the ATP-binding
cassette (ABC) transporter superfamily plays a role in resistance
to pentamidine and cross-resistance to trivalent antimonials in
Leishmania when over expressed (Figure 3) (Coelho et al., 2003,
2006, 2007, 2008). PRP1 is an intracellular protein possibly
associated with the tubulovesicular element that is linked to the
exo- and endo-cytosis pathway (McConville et al., 2002; Coelho
et al., 2006).
Eflornithine, is an inhibitor of ornithine decarboxylase, an
essential enzyme for the first step of polyamine synthesis and the
formation of trypanothione (Bacchi et al., 1980). The drug crosses
the blood-brain barrier and its entry into trypanosomes is also
transporter-mediated. Several groups have recently identified the
amino acid transporter TbAAT6 as responsible for eflornithine
uptake showing that its lost is associated to drug resistance
(Figure 2) (Vincent et al., 2010; Baker et al., 2011; Schumann
Burkard et al., 2011). However, this mechanism of resistance to
eflornithine still remains to be confirmed in resistant parasites
from clinical isolates.
Pentavalent antimonials are considered as pro-drugs
which are further converted to trivalent antimonials or
antimonites, the active forms of the drug. The mechanism
of action seems to be multifactorial, including inhibition of
macromolecular biosynthesis (Berman et al., 1985), likely by
targeting glycolysis and fatty acid oxidation (Berman et al., 1987).
DNA fragmentation and externalization of phosphatidylserine
on the outer surface of the plasma membrane have been also
reported (Sereno et al., 2001; Lee et al., 2002; Sudhandiran and
Shaha, 2003). However, the specific targets in these pathways
have not been identified. Metabolism of thiol is essential in the
mechanism of action of antimonials. Trypanothione is the major
thiol in Leishmania. Antimonites exhibit in vitro inhibition of
trypanothione reductase, an enzyme responsible for protection
of parasites from host reactive oxygen and nitrogen species
(Wyllie et al., 2004).
The route of entrance of antimonial drugs into Leishmania
remains elusive. The surface transporter aquaglyceroporin 1
has been shown to facilitate trivalent antimonial entrance, and
its overexpression renders Leishmania cells hypersensitive to
antimonials (Gourbal et al., 2004).
Frontiers in Pharmacology | www.frontiersin.org 4 September 2016 | Volume 7 | Article 351
fphar-07-00351 September 26, 2016 Time: 16:52 # 5
Garcia-Salcedo et al. Approaches to Overcome Drug Resistance
FIGURE 2 | Drug transporters in T. brucei.
FIGURE 3 | Drug transporters in Leishmania. K, kinetoplast; N, nucleus.
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Mechanisms responsible for antimonial acquired resistance
in clinical isolates have been studied for several decades, but
the results are puzzling. Clinical isolates are characterized by
presenting high variability in the mechanism as well as in
the degree of resistance (Mukherjee et al., 2007). Resistant
Leishmania cells to antimonials have been selected in vitro and
some resistance mechanisms have been suggested, including
reduced accumulation (Dey et al., 1994) and loss of reduction of
the pentavalent metal (Shaked-Mishan et al., 2001).
ABC transporters use the hydrolysis of ATP to translocate
a variety of compounds across biological membranes. Some
ABC transporters play a major role in resistance of tumors
to anticancer drugs (Fletcher et al., 2016), and antibiotic
resistance in pathogenic microorganisms (Klein et al., 2011;
Leprohon et al., 2011). Previous studies have reported the
role of ABC transporters in Leishmania-acquired antimonial
resistance (Figure 3). Gene amplification of ABC pumps has
been associated with resistance to antimonials in laboratory-
derived and clinical isolate-resistant parasites (Ferreira-Pinto
et al., 1996; Haimeur and Ouellette, 1998; Haimeur et al.,
2000; Mukherjee et al., 2007; Mandal et al., 2009; Manzano
et al., 2013, 2014; Perea et al., 2016). Overexpression of ABC
transporters regulates the elimination of antimonites through
two different routes: their sequestration into the intracellular
vacuolar compartment or direct eﬄux across the plasma
membrane. A different mechanism includes the modulation
of macrophage drug transporters and metabolizing enzymes
related to resistance to antimonials. Infection with an antimonite-
resistant Leishmania strain upregulated multidrug resistance-
associated protein 1 (MRP1) and permeability glycoprotein
(P-glycoprotein) in host cells, leading to the inhibition of
intracellular drug accumulation by reducing antimonite influx
(Figure 3) (Mukherjee et al., 2007; Mandal et al., 2009).
Antimonial resistance is also associated with aquaglyceroporin 1
transporter. Down-regulation of aquaglyceroporin 1 is correlated
with lower antimonite uptake, leading to a decrease in drug
concentration within the parasite (Figure 3) (Marquis et al.,
2005).
Amphotericin B is a polyene drug with selective activity
against fungi, Leishmania and T. cruzi due to its higher affinity
for ergosterol, the predominant sterol in these pathogens over
cholesterol, the predominant sterol in mammalian host cells.
Amphotericin B induces the formation of small membranous
pores that alter membrane permeability toward cations, water,
and glucose molecules (Ramos et al., 1996).
Mechanisms of drug resistance to amphotericin B developed
by Leishmania are various and include: (i) a change in membrane
fluidity; (ii) a decrease in thiol and reactive oxygen species
levels likely due to a hyperactivity tryparedoxin cascade; and
(iii ) an increase in drug eﬄux from the cell (Purkait et al.,
2012). An RT-PCR analysis of clinical isolates of L. donovani
has shown the upregulation of several genes implicated
in trypanothione biosynthesis and the tryparedoxin cascade.
Furthermore, the mRNA level of the ABC transporter MDR1 was
found to be four-fold higher in R-strains which supported the
observations for increased drug eﬄux (Figure 3) (Purkait et al.,
2012).
Miltefosine (hexadecylphosphocholine) is a membrane-
active alkyl phospholipid that was originally developed as an
anticancer drug. Currently, it is used as the first-line treatment
for visceral leishmaniasis and was considered a major step
forward in antileishmanial therapy (Jha et al., 1999; Sundar
et al., 2006). The precise mode of action remains largely
unknown. Miltefosine reduces the lipid content and augments
the phosphatidylethanolamine content in the parasite membrane,
suggesting a partial inhibition of phosphatidylethanolamine-
N-methyltransferase which causes a delay in cell proliferation
(Loiseau and Bories, 2006). Miltefosine also triggers an apoptosis-
like cell death in Leishmania (Paris et al., 2004; Alzate et al., 2008;
Khademvatan et al., 2011; Marinho Fde et al., 2011) but it is
unknown how this happens.
Miltefosine activity is due to intracellular accumulation of
the drug, which is regulated by two transporters, the miltefosine
transporter LdMT, a novel P-type ATPase member of the
aminophospholipid translocase family and its beta subunit
LdRos3 (Figure 3) (Perez-Victoria et al., 2003; Perez-Victoria
F.J. et al., 2006). Reported resistances are associated with a
severely diminished intracellular drug concentration, due to
the overexpression of eﬄux pumps and, mainly, to the failure
of miltefosine transporters (Perez-Victoria J.M. et al., 2006).
Furthermore, low expression of the LdRos3 subunit is the cause
of natural resistance to miltefosine observed in Leishmania
(Sanchez-Canete et al., 2009). Clinical resistances have been
recently isolated and most of them are associated with punctual
mutations in the LdMT transporter (Cojean et al., 2012).
Paromomycin (aminosidine) is an aminoglycoside pro-
duced by Streptomyces rimosus with both antibacterial and
antileishmanial activity (No, 2016). The drug was licensed in 2006
and field resistance has not yet been reported.
Nifurtimox and benznidazole are nitroheterocyclic drugs
carrying a nitro group linked to an aromatic ring that function
as prodrugs and must undergo a reductive activation within the
parasite to have cytotoxic effects. This reaction is catalyzed
by NADH-dependent bacterial-like nitroreductase and
drug-induced resistant parasites arise as a consequence of
mutations in this enzyme (Wilkinson et al., 2008; Campos et al.,
2014). In addition, P-glycoprotein eﬄux and P-glycoprotein
ATPase activity have been described in T. cruzi resistant to
nitroheterocycles, implicating ABC eﬄux pumps in drug
resistance (Campos et al., 2013). Resistance to nitroheterocycles
seems to be due to qualitative differences in P-glycoprotein
function (Murta et al., 2001) and P-glycoprotein gene
overexpression (Franco et al., 2015; Zingales et al., 2015).
STRATEGIES TO SPECIFICALLY
OVERCOME TRANSPORT RELATED
DRUG RESISTANCE
Efflux Pumps Inhibition
Among the different drug resistance mechanisms previously
described, those based on decreasing the drug concentration
at the target site by drug movement through the membranes
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appear to play an important role in Leishmania and T. cruzi.
Hence, inhibition of the activity of ABC transporters represents
an interesting strategy for controlling drug resistance.
A number of compounds have been identified to inhibit
P-glycoproteins which are as diverse as calcium channel blockers,
calmodulin antagonists, protein kinase inhibitors, antibiotics,
hydrophobic peptides, hormone derivatives, and flavonoids.
Their effectiveness in reversing acquired drug resistance in
Leishmania varies greatly between species and cell cycle stages
due to marked differences in the expression of their target, ABC
transporters.
Verapamil, a calcium channel blocker, has been employed
to reverse drug resistance to antimony associated with the
overexpression of several P-glycoproteins and MRP in
Leishmania and T. cruzi strains obtained in the laboratory
(Neal et al., 1989; BoseDasgupta et al., 2008) and from clinical
isolates of Leishmania (Valiathan et al., 2006). Verapamil is
also able to overcome resistance to pentamidine in Leishmania
(Basselin et al., 2002; Coelho et al., 2008) but its effectiveness is
species dependent (Mukherjee et al., 2006).
Calmodulin antagonists have been shown to reverse
drugs resistance in parasites. Phenothiazine derivates such
as chlorpromazine increased sensitivity to antimonials in
multidrug resistant L. donovani and L. major strains in vitro
(el-On et al., 1986). These compounds have antiprotozoal activity
per se (Pearson et al., 1984; Werbovetz et al., 1992). However,
the study of phenothiazine derivates has been abandoned due
to the high rate of toxicity founded in its leading molecule
chlorpromazine.
Statins, also known as HMG-CoA reductase inhibitors, are
drugs currently used to lower the level of low-density lipoprotein
(LDL) in the blood preventing atherosclerosis and cardiovascular
disease. Besides this lipid-lowering activity, statins also inhibit
ABC transporters. Lovastatin, a member of the statin family,
in combined therapy with the antifungal drug miconazole,
reduced Leishmania cell growth and macrophage infection,
although the proposed mechanism of action by lovastatin was
through inhibition of sterol biosynthesis (Haughan et al., 1992).
Lovastatin has been shown to inhibit MRP1 and P-glycoprotein
in L. donovani allowing antimony accumulation and parasite
killing within macrophages (Mookerjee Basu et al., 2008).
Moreover, pretreatment with lovastatin in hamsters infected with
an antimonial-resistant L. donovani cell line reversed acquired
resistance to antimonials.
Flavonoids constitute a class of natural inhibitors of
P-glycoprotein and related ABC transporters in Leishmania
(Perez-Victoria et al., 1999; Wong et al., 2007; Kennedy
et al., 2011). Quercetin, a flavonoid that regulates human
ABC transport by reducing P-glycoprotein synthesis reduced
miltefosine accumulation in Leishmania (Castanys-Munoz et al.,
2007). Synthetic flavonoid dimmers have been used to reverse
drug resistance to antimony and pentamidine in L. donovani by
increasing intracellular drug accumulation (Wong et al., 2007).
Sesquiterpenes are natural products that overcome multidrug
resistance in Leishmania including resistance to miltefosine.
Sesquiterpene C3 fully sensitized a multidrug resistant
Leishmania by increasing intracellular drug concentration
through the modulation of new ABC transporter activity
(Perez-Victoria et al., 2001).
Drug Transporters
A different strategy to defeat drug resistance associated with
surface transporters is the use of drug delivery systems.
Nanoparticles of biodegradable and biocompatible polymers
are widely used for this purpose. Specific cell-surface targeting
has been shown to be an effective strategy to overcome
drug resistance associated with the loss of function of surface
transporters responsible for drug uptake in T. brucei. PEGylated
PLGA nanoparticles were coupled to a single-domain heavy-
chain antibody fragment (nanobody) that specifically recognizes
the surface of the parasite (Figure 4) (Stijlemans et al., 2004).
Nanoparticles were loaded with pentamidine, the first-line drug
for T. b. gambiense acute infection. An in vitro and in vivo
effectiveness assay demonstrated that the formulation was able
to significantly reduce the effective drug concentration (Arias
et al., 2015). Moreover, an improved version of this nanocarrier
reduced the curative dose 100-fold and most significantly,
circumvented drug resistance as a result of mutations in
aquaglyceroporin 2 (Unciti-Broceta et al., 2015), the surface
channel protein that mediates pentamidine uptake in T. brucei
(Baker et al., 2012). This study represents a proof-of-concept as
a strategy for overcoming drug resistance linked to the loss of
function of surface transporters.
Cell-penetrating peptides, also known as peptide transduction
domains, membrane translocating sequences and Trojan
peptides, are short peptides with the ability to enter almost any
cell. In the late 1980s it was observed that the trans-activator
of transcription (TAT) of the HIV virus as well as a chemically
synthesized version of TAT was able to enter cells (Frankel and
Pabo, 1988; Green and Loewenstein, 1988). Cell-penetrating
peptides are highly cationic and usually rich in arginine and lysine
amino acids. Their exceptional property of delivering into the cell
a wide variety of cargoes such as proteins, oligonucleotides and
even 200 nm liposomes has made them attractive candidates to
transport drugs to the interior of cells (van den Berg and Dowdy,
2011). The cargo is associated with the peptides either through
chemical linkage via covalent bonds or through non-covalent
interactions, and they get inside cells primarily via endocytosis
but also by direct membrane penetration.
Conjugation of miltefosine to the cell penetrating peptide
TAT has been applied as an efficient strategy to defeat drug
resistance associated with lack of function of the LdMT
surface transporter in Leishmania (Luque-Ortega et al., 2012).
Functionalized miltefosine carrying a thiol group was conjugated
to TAT48−60 through either a disulphide or a thioether bond.
Drug conjugates were able to enter and kill both promastigote
and intracellular amastigote forms of a Leishmania-resistant
strain. Intracellular release of the drug was not a requirement
since the most metabolically stable thioether conjugate retained
significant leishmanicidal activity compared to the less stable
disulphide conjugate.
The strategy was also applied to kill T. brucei, a parasite
naturally insensitive to miltefosine due to the lack of the surface
translocase system responsible for drug uptake (Luque-Ortega
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FIGURE 4 | Strategy to overcome drug resistance associated to mutations in surface transporter in T. brucei based on nanobody-coated
pentamidine loaded nanoparticle.
et al., 2012). This report provides proof-of-mechanism for the use
of cell-penetrating peptide conjugates to bypass drug resistance
due to diminished intracellular drug concentration in parasites,
and open the possibility to extend chemotherapy into other
parasites intrinsically devoid of membrane translocation systems.
STRATEGIES WITH POTENTIAL TO
OVERCOME RESISTANCE
Cyclodextrins are cyclic oligosaccharides, with a hydrophilic
outer surface and a hydrophobic interior cavity. Cyclodextrins
are able to form water-soluble inclusion complexes with many
poorly soluble lipophilic compounds, and have been widely
used to enhance drug solubility and reduce drug toxicity
(Zhang and Ma, 2013). Melarsoprol, a highly toxic drug for
treating the late stage of human African trypanosomiasis,
has been successfully occluded within two different types
of cyclodextrin: β-cyclodextrin and randomly methylated-
β-cyclodextrin (Rodgers et al., 2011). These compounds retained
trypanocidal activities in vitro and cured the late stage of the
disease in a murine model.
The entrance route of melarsoprol-cyclodextrin complexes
is probably different than that of free melarsoprol. Entry of
the drug with cyclodextrin is likely via endocytosis whereas
that of free melarsoprol is via the aquaglyceroporin 2 channel.
As mentioned before, resistance to melarsoprol in clinical
isolates correlates with mutations in aquaglyceroporin 2 surface
transporter. Therefore, although it has not been tested, it is quite
possible that the melarsoprol-cyclodextrin formulation could
circumvent melarsoprol resistance.
Biopharmaceutical issues are more complex in the case of
intracellular parasites such as Leishmania or T. cruzi. The
design of drug delivery systems must take into account aspects
like passage through physical barriers and cell membranes,
the mechanism of cellular uptake, stability, activity and
kinetics of the drug in the target cell environment. The
pharmacodynamic response of antiparasitic drugs is governed
in intracellular parasites by the drug concentration reached
inside host cells rather than that in the circulatory system
(Date et al., 2007). In general, drug delivery systems increases
efficacy and reduce side effects relative to free drug. It
has also been reported that these systems can increase
susceptibility to drug in resistant parasites by increasing drug
concentration inside targeted host cells, but there are very few
specific studies about circumventing drug resistance (Yasinzai
et al., 2013). However, It has been described the use of
nanodevices to encapsulate alternative drugs for treatment of
resistance to a drug. (Yasinzai et al., 2013; Gutierrez et al.,
2016).
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Leishmania is a good model to be targeted by these
nanoformulations because it only parasitizes macrophages which
are responsible for the clearance of blood particulate materials
in vivo. Liposomes, niosomes, nanoemulsions, nanodiscs,
transfersomes, solid lipid nanoparticles, polymeric and metalic
micro/nanoparticles and other delivery systems have been
extensively investigated for the treatment of leishmaniasis (Date
et al., 2007; Gupta et al., 2010; Yasinzai et al., 2013; Gutierrez et al.,
2016). Liposomes are the most frequently used drug delivery
systems for leishmaniasis treatment. It is described that liposomes
deliver their contents into the macrophage cytoplasm by fusing
their membrane to the plasma membrane of the cells, increasing
the drug concentration inside it. Different types of liposomes
have been developed for both passive and active targeting
of macrophages. These formulations included conventional
liposomes and arsonoliposomes (containing arsenolipids with
covalently linked arsenic) for passive targeting and sugar-bearing
liposomes (mannose, or neoglycoprotein); positively charged
liposomes (containing phosphatidyl choline or stearyl amine);
peptide-grafted liposomes (with macrophage-activating peptides
like tuftsin or the chemotactic peptide f-Met-Leu-Phe) and
immunoliposomes (IgG-coupled liposomes) for active targeting
of macrophages. A commercial preparation of Amphotericin B
in liposomes (AmBisome) was approved for treatment of visceral
leishmaniasis as the first choice for the treatment of resistance
associated with antimonials (Ng et al., 2003). It has also been
shown that liposomal miltefosine improved the susceptibility of
miltefosine-resistant Leishmania promastigotes (Papagiannaros
et al., 2005). In vitro investigations on arsonoliposomes
revealed that they were active against amphotericin B and
miltefosine-resistant L. donovani at relatively low concentrations
of arsenolipids (Antimisiaris et al., 2003).
Various polymeric nanoparticulate or micellar systems of
polyalkylcyanoacrylate, polylactic acid, poly (lactic co-glycolic
acid), poly(ε-caprolactone), chitosan, albumin, gelatin, lipid
and inorganic nanoparticles (gold, silver, titanium oxide,
etc) were also tested for the treatment of leishmaniasis
(Date et al., 2007; Gupta et al., 2010; Pham et al., 2013;
Yasinzai et al., 2013; Gutierrez et al., 2016). Some particulate
nanocarriers can cross biological barriers by endocitosis-like
mechanisms and could be appropriate to target intracellular
parasites like Leishmania. Ultrastructural studies indicated
that nanoparticles were concentrated in the phagolysosome,
quite close to Leishmania amastigotes, releasing the drug
into the macrophage cytoplasm (Fusai et al., 1997). PLGA
nanoparticles loaded with the antiparasitic drug andrographolide
and stabilized the excipient vitamin E-TPGS (D-a-tocopheryl
polyethylene glycol 1000 succinate) which is an inhibitor of
the P-glycoprotein eﬄux pump showed high effectivity against
wild and multidrug resistant L. donovani strains in vitro
(Mondal et al., 2013). In this context, piperolactam A loaded
hydroxypropyl-β-cyclodextrin nanoparticles have also proved
effective against wild and multiresistant L. donovani in vitro
(Bhattacharya et al., 2016). Previous studies showed that
some metal and metal oxide nanoparticles have antimicrobial
activity by generation of reactive oxygen species. These
nanoparticles have been assayed against drug-resistant bacteria
and Leishmania parasites (Allahverdiyev et al., 2011; Das
et al., 2013; Jebali and Kazemi, 2013). After exposure to
nanoparticles, the highest antileishmanial activity was observed
for Ag-nanoparticles, followed by Au, TiO2, ZnO, and MgO
nanoparticles. Both ultraviolet and infrared light increased the
antileishmanial properties of all nanoparticles. Unfortunately,
despite their significant potential in antimicrobial applications,
the toxicity of metal oxide nanoparticles has restricted their
use. Nevertheless, recent studies using crystalline nanoparticles
of ZnCuO showed better biocompatibility indicating that metal
oxide nanoparticles in resident non-toxic form have considerable
potential for antibacterial and antiparasitic applications in the
future (Nadhman et al., 2015).
Transfersome is a nanocarrier designed for drug delivery
across the skin barrier. Transfersome formulations bearing
amphotericin B have been tested against sensitive and resistant
clinical isolates of L. donovani and compared with the
conventional liposomal formulation and free amphotericin B.
Transfersome formulations were significantly more active than
conventional liposomes and free amphotericin B suggesting
improved penetration and better partitioning in skin layers.
Transfersomes were also able to partially reverse resistance
to amphotericin B. Nevertheless, potential utilities of these
novel formulations as an alternative chemotherapeutic approach
for the treatment of resistant leishmaniasis necessitate further
investigations (Singodia et al., 2010).
In the case of Chagas disease, there is few research works
published in the context of drug delivery systems and only
in some of them resistance is mentioned. There are two
main challenges in Chagas disease therapy using drug
carriers, the first one is to reach disseminated intracellular
parasites (in cardiac, skeletal and smooth muscle, glial cells,
etc.) at therapeutic doses and the second is the selectivity
for target cells since current drugs are toxic. Different
nano-formulations have been assayed, including liposomes,
polyalkylcyanoacrylate nanospheres, poly(ethyleneglycol)-co-
poly(lactic acid) nanoparticles, dendrimers, and other lipid
formulations. In general, these formulations had limited efficacy
relative to free drug with the only advantage of reducing
toxicity (Romero and Morilla, 2010; Salomon, 2012; Morilla
and Romero, 2015). Low endocytic activity of host forms of the
parasite (trypomastigote and amastigote), target selectivity and
the selected nanocarrier could be responsible for this lack of
effectiveness. Nevertheless improvements in nanocarriers design
like pH-sensitive formulations, passive and active targeting,
prodrug dendrimers, nitric oxide-releasing nanoparticles, etc.,
could improve drug efficacy (Romero and Morilla, 2010; Morilla
and Romero, 2015; Seabra et al., 2015).
CONCLUDING REMARKS
Diseases caused by trypanosomatids are a serious health and
socioeconomic problem, in particular in developing countries.
The lack of effective vaccines, old and unsafe drugs, along with
the emergence and spread of resistance, has recently led to the
launch of campaigns supporting the battle against these diseases.
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However, the discovery and development of new drugs have been
slowed by the high cost associated with processing new molecules
through the long drug discovery pipeline together with the poor
financial motivation for pharmaceutical companies. However,
recent advances in the elucidation of drug resistance mechanisms
have led to the development of new therapeutic approaches with
the ability of restoring/improving the efficacy of the existing
drugs.
In trypanosomatids, resistance mechanisms are often
associated with changes in the function or quantity of surface
transporters leading to a lower of drug uptake or increased
eﬄux. The loss of function of surface transporters responsible
of drug uptake is a common mechanism of drug resistance in
African trypanosomes (Munday et al., 2015) and overexpression
of multidrug export transporters such as eﬄux pumps play
a key role in the emergence of resistance in Leishmania and
to lesser extent in T. cruzi (Leprohon et al., 2011). Currently,
both mechanisms have become the focus of research for the
development of new therapeutic tools to recover previously failed
compounds. The inhibition of the activity of ABC proteins has
been well studied for cancer and represents an interesting way to
control drug resistance associated with enhanced drug eﬄux in
protozoan parasites. However, although drug resistance is not a
serious problem for the treatment of Chagas disease, the use of
eﬄux pumps inhibitors to reverse resistance in T. cruzi is scarce
and deserves to be explored more deeply.
The use of an alternative drug entrance route has also
proved to be a successful approach to overcome drug resistance
associated with mutations that reduce drug import. Passive
(cell penetrating peptides) and active (nanobodies) targeting
engineered nanosystems can be used to introduce exiting
drugs into the parasite that avoid the cell surface transporters
involved in drug up take. Both are proofs of concept of
strategies capable of reversing resistance to many first-line
treatments. Efforts should be made in the design of drug
delivery systems to improve the effectiveness of current
nanoformulations targeting intracellular forms of Leishmania
and T. cruzi.
In summary, all these novel approaches open a new way to
develop and test promising anti-parasitic tools. These advances,
combined with the constant evolution of the nanomedicine, may
portend new effective developments in the treatment of diseases
caused by trypanosomatids.
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